NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have forged a robust strategic alliance aimed at shaping the future landscape of global health and wellness. Drawing upon their respective proficiencies and groundbreaking research in coenzymes and NAD+, both entities are united in their vision to pioneer advanced NAD-based therapeutics and supplements, catering to those aspiring for enhanced longevity, vitality, and well-being.
The formalization of this collaboration occurred on May 6, 2024, marked by the signing of a partnership cooperation agreement between Bontac Bio-Engineering (Shenzhen) Co., Ltd and NADclinic Group, signifying their mutual aspiration to deepen strategic ties.
Nicotinamide Adenine Dinucleotide (NAD+) stands as a pivotal coenzyme in cellular metabolism, ubiquitous across all living organisms. Its indispensability lies in its role in converting glucose into cellular energy, thereby facilitating a healthier aging process, sustaining metabolic functions, supporting DNA repair, mitigating inflammation, and fortifying resistance against diseases and chronic ailments. With involvement in over 500 crucial enzymatic reactions within the body, NAD+ emerges as a linchpin of human biology.
The partnership between NADclinic and Bontac Bio-Engineering (Shenzhen) Co., Ltd underscores their shared commitment to advancing global NAD+ research and jointly innovating science-backed approaches to optimize bioavailability and delivery methods, thereby fostering enhanced patient outcomes. As the global NAD+ market experiences rapid expansion, this collaboration ensures both entities remain at the vanguard of preventive health innovation, human performance enhancement, and longevity pursuits.
This synergy capitalizes on Bontac Bio-Engineering (Shenzhen) Co., Ltd’s expertise in coenzyme APIs, NAD+ raw materials, and NAD-based product development, complemented by NADclinic’s expansive global presence and pioneering research and development in NAD+ therapy. NADclinic, renowned for its innovative IV protocols, therapeutics, and supplements, is enthusiastic about the collaboration and the prospects it holds for the future.
Iain De Havilland, Founder and CEO of NADclinic, articulated, “At NADclinic, we are dedicated to spearheading advancements in NAD+ therapeutics and nutraceuticals to empower individuals towards longer, healthier, and more vibrant lives. Our collaboration with Bontac Bio-Engineering (Shenzhen) Co., Ltd perfectly aligns with our mission, enabling us to pool our expertise and resources to deliver unparalleled solutions globally.”
Professor Zhang Qi, Chief Scientist and Founder of Bontac Bio-Engineering (Shenzhen) Co., Ltd, expressed similar enthusiasm, stating, “We are excited to partner with NADclinic, sharing a mutual commitment to excellence and innovation in NAD+ therapy. Through this collaboration, we aim to leverage our combined expertise to provide individuals worldwide with access to top-quality NAD+ products, supporting their journey to improved health and vitality.
